^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG:

    BiovaxID (dasiprotimut-T)

    i
    Associations
    News

    Trials

    Company:
    Accentia, National Cancer Institute
    Drug class:
    Immunostimulant
    Related drugs:
    Associations
    News

    Trials

    Apply
    Chemotherapy Plus Vaccination to Treat Mantle Cell Lymphoma (NCT00005780)
    Phase 2
    National Cancer Institute (NCI)
    Completed
    Last update posted :
    01/31/2023
    Initiation :
    06/01/2000
    Primary completion :
    06/09/2021
    Completion :
    06/16/2021
    CD4
    |
    Rituxan (rituximab) • doxorubicin hydrochloride • cyclophosphamide • etoposide IV • vincristine • prednisone • BiovaxID (dasiprotimut-T) • Leukine (sargramostim)